Extended Data Fig. 9: No sign of recurrence at four weeks off-treatment following a four-week course of AZD5582/venetoclax combination.

a,b, Human CD45-labeled and HE-stained thin sections of femurs from (a) untreated and (b) AZD5582/venetoclax combination-treated Patient 2 PDX mice. White broken lines in HE-stained images outline blood vessels containing erythrocytes. Arrows indicate hCD45-negative murine megakaryocytes. c, Thin sections of femurs from untreated and AZD5582/venetoclax treated PDX-model mice for five AML patients are shown as indicated. The sections were labeled with human CD45 (three panels on the left for each patient) or with HE (two panels on the right for each patient). AZD5582/venetoclax treated mice were first engrafted with patient-derived AML cells then underwent a four-week course of treatment followed by over four weeks off-treatment. The lengths of the scale bars are indicated in panels for Patient 9.